Skip to content
Medical Health Aged Care

New Guiding Principles to improve incontinence medication safety for people living with dementia

Monash University 2 mins read

Monash University researchers are today launching the first co-designed resources to safely guide the use of urinary incontinence medications for people living with dementia.

 

Doctors routinely prescribe medications to manage urinary incontinence, but the medications can carry hidden dangers for people with dementia, increasing the risk of side effects such as worsening memory loss. 

 

Despite the risks, the healthcare sector previously lacked evidence-based co-designed resources to help families and healthcare professionals decide when to start or stop treatment.

 

Dr Amanda Cross, who developed the 10 Guiding Principles with her team from the Centre for Medicine Use and Safety at the Monash Institute of Pharmaceutical Sciences, said the resources aim to close the gap.

 

“There are multiple ways to approach incontinence care for a person living with dementia, but when medication is considered, it requires a very careful balancing act to ensure the benefits outweigh the risks,” Dr Cross said.

 

“There is often limited evidence to guide decision making for medication use for people with dementia, so the Guiding Principles help healthcare professionals navigate the difficult conversations.

 

“The Guiding Principles were also shaped by lived and living experience at every single stage – and were created to empower people living with dementia and their families to engage in shared decision-making with their healthcare team to ensure treatment aligns with the patient’s individual care goals.”

 

Launched to coincide with World Continence Week, a global campaign encouraging individuals to seek appropriate medical advice, the complete suite of resources is available here and includes:

 

  • 10 Guiding Principles to support the safe and appropriate use of medications for the management of urinary incontinence in people living with dementia – Healthcare professional version

  • 10 Guiding Principles to support the safe and appropriate use of medications for the management of urinary incontinence in people living with dementia – Consumer version

  • Medication summary table that compares safety and efficacy of medications for urinary incontinence for people with dementia, to be used together with the 10 Guiding Principles

The initiative was funded by a Dr Stuart and Bonnie Bartle Project Grant from the Dementia Australia Research Foundation.

 

MEDIA ENQUIRIES 

 

Philip Ritchie
Media and Communications Manager

P: +61 430 336 243

E: [email protected] 

 

GENERAL MEDIA ENQUIRIES

 

Monash Media

P: +61 3 9903 4840

E: [email protected]

 

For more experts, news, opinion and analysis, visit Monash News.

More from this category

  • Medical Health Aged Care
  • 16/06/2026
  • 22:47
Optimi Health Corp.

Optimi Health Launches Standardized Microdose Psilocybin Products for Clinical Research

Two naturally derived finished drug products, at 1mg and 2mg, give research organizations the consistent, validated doses required for controlled studiesNew microdose formats extend Optimi's psilocybin range, which includes a 5mg formulation currently commercially prescribed for treatment-resistant depression in Australia under the country's Authorized Prescriber SchemeVANCOUVER, British Columbia, June 16, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the "Company" or "Optimi"), a commercial-stage GMP pharmaceutical manufacturer of regulated psychedelic drug products, today announced it has completed production of two microdose psilocybin finished drug products, formulated at 1 mg and 2 mg dosages. The products…

  • Medical Health Aged Care
  • 16/06/2026
  • 14:30
Dementia Australia

Brisbane comes together for people impacted by dementia

Brisbane community members tied up their laces and showed up in force last weekend for the 2026 Brisbane Memory Walk & Jog - throwing their support behind people impacted by dementia whilst getting active to improve their brain health. More than 1,470 people walked, ran and jogged to the finish line to raise an impressive total of $195,098. Dementia Australia CEO Professor Tanya Buchanan extended her gratitude to all who participated, volunteered and raised vital funds for the cause. “There was an incredible turnout from the Brisbane community this year yet again, in support of the many people impacted by…

  • Contains:
  • Biotechnology, Medical Health Aged Care
  • 16/06/2026
  • 09:51
ENA Respiratory

ENA Respiratory Receives USPTO Notice of Allowance for Two Patents Covering TLR2 Agonists and Rhinovirus-Mediated COPD Exacerbations

Melbourne, Australia, 15 June 2026 – ENA Respiratory, a clinical-stage pharmaceutical company developing innate immune modulators for the prevention of complications associated with respiratory viral infections in at-risk populations, announces today that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for two patent applications notably a composition-of-matter patent and method-of-use for its Toll-like receptor 2 (TLR2) therapies. A composition-of-matter patent (US 17/622,451, "A series of TLR2 agonist compounds") and A method-of-use patent for the treatment of rhinovirus-mediated exacerbations of chronic obstructive pulmonary disease (COPD) (US 16/495,829, "Methods of treating rhinovirus-mediated exacerbations of COPD…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.